Valtis, Yannis K.
Flamand, Yael
Shimony, Shai http://orcid.org/0000-0001-7245-9652
Place, Andrew E.
Silverman, Lewis B.
Vrooman, Lynda M.
Brunner, Andrew M. http://orcid.org/0000-0002-2169-4115
Sallan, Stephen E.
Wadleigh, Martha
Stone, Richard M.
DeAngelo, Daniel J. http://orcid.org/0000-0001-7865-2306
Luskin, Marlise R. http://orcid.org/0000-0002-5781-4529
Article History
Received: 5 June 2023
Revised: 4 December 2023
Accepted: 7 December 2023
First Online: 5 January 2024
Competing interests
: YV received a consultancy fee from EastRx. LS was on the advisory board of Jazz Pharma, Takeda, Servier, and Syndax. AB received consultancy funding from Acceleron Pharma, Biogen, Celgene/BMS, Forty Seven, Jazz Pharma, Novartis, Takeda, and Xcenda, and research funding from Celgene/BMS, Novartis, Takeda, GSK, Janssen, and Astra Zeneka. DD received consultancy funding from Amgen, Autolos, Agios, Blueprint Medicines Corporation, Forty Seven, Incyte Corporation, Jazz Pharma, Novartis, Pfizer, Shire, and Takeda, and research funding from Bluperint Medicines Corporation, Novartis, Abbvie, and Glycomimetics. MRL received research funding from AbbVie, Novartis and was on advisory boards Pfizer, Novartis.